Stock Analysis

Jupiter Life Line Hospitals Second Quarter 2025 Earnings: EPS: ₹7.86 (vs ₹5.67 in 2Q 2024)

NSEI:JLHL
Source: Shutterstock

Jupiter Life Line Hospitals (NSE:JLHL) Second Quarter 2025 Results

Key Financial Results

  • Revenue: ₹3.32b (up 24% from 2Q 2024).
  • Net income: ₹515.1m (up 53% from 2Q 2024).
  • Profit margin: 16% (up from 13% in 2Q 2024). The increase in margin was driven by higher revenue.
  • EPS: ₹7.86 (up from ₹5.67 in 2Q 2024).
earnings-and-revenue-growth
NSEI:JLHL Earnings and Revenue Growth November 10th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jupiter Life Line Hospitals Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India.

Performance of the Indian Healthcare industry.

The company's shares are up 5.4% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Jupiter Life Line Hospitals that you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.